Savara Inc. | Clinical-stage Biopharmaceutical Company
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Learn more.
Our Company - Savara Inc.
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Press Releases | Investors - Savara Inc.
Sep 27, 2024 · Explore events and presentations. Stay up-to-date with Savara’s latest press releases and access previous press releases in our archive, organized by year.
Clinical Trials | In Develoment - Savara Inc.
Learn more about Savara’s clinical research in potential treatments for rare respiratory diseases including aPAP.
What is aPAP? | Our Science - Savara Inc.
With aPAP, a buildup of surfactant forms in the alveoli (air sacs) of the lungs. Surfactant is a substance that lines the alveoli and prevents the lungs from collapsing. The root cause of aPAP is an autoimmune response against granulocyte-macrophage colony-stimulating factor (GM-CSF).
Molgramostim Nebulizer Solution in aPAP | In Develoment
Molgramostim nebulizer solution (molgramostim) is a non-glycosylated form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Savara is developing an inhaled formulation as a potential treatment option for aPAP.
Events & Presentations | Investors - Savara Inc.
May 14, 2024 · Explore Savara stock performance. View Savara’s upcoming events & presentations. Past events and presentations are also listed in date order beginning with the most recent.
Careers - Savara Inc.
Working at Savara. At Savara, our team is comprised of motivated, energized, and compassionate people who are focused on improving the lives of patients with rare respiratory diseases.
Articles and Publications | In Develoment - Savara Inc.
Learn more about Savara’s ongoing initiatives from our articles and publications. Read presentations, download posters, and more.
SEC Filings | Investors - Savara Inc.
Jul 25, 2024 · Statement of changes in beneficial ownership of securities. View the list of the latest SEC filings from Savara Inc. in chronological order, in multiple file formats.